Stock Analysis

Yantai Zhenghai Biotechnology Third Quarter 2024 Earnings: EPS: CN¥0.21 (vs CN¥0.21 in 3Q 2023)

SZSE:300653
Source: Shutterstock

Yantai Zhenghai Biotechnology (SZSE:300653) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥93.3m (down 4.1% from 3Q 2023).
  • Net income: CN¥39.0m (up 1.4% from 3Q 2023).
  • Profit margin: 42% (up from 40% in 3Q 2023). The increase in margin was driven by lower expenses.
  • EPS: CN¥0.21 (in line with 3Q 2023).
earnings-and-revenue-growth
SZSE:300653 Earnings and Revenue Growth October 23rd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Yantai Zhenghai Biotechnology Earnings Insights

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 3.5% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Yantai Zhenghai Biotechnology.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.